Bio-Techne Expands AI-Engineered Protein Portfolio
Bio-Techne Corporation has expanded its R&D Systems™ AI-Engineered Designer Protein portfolio with new heat-stable and hyperactive proteins. These products aim to enhance cell therapy scalability and reproducibility, as well as advanced cell culture workflows.
Bio-Techne Corporation has added new proteins designed with artificial intelligence to its R&D Systems™ portfolio.
The expansion includes heat-stable and hyperactive proteins within the fibroblast growth factor and interleukin cytokine families. These new offerings are intended to improve the scalability and reproducibility of cell therapy processes and facilitate advanced cell culture workflows.
The protein design process utilized AI to accelerate cell research and its applications.
These new proteins provide researchers with enhanced tools for developing cell-based therapies and research studies.